Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 3NCT02453282
Official study title

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Study summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMEDI4736 (Durvalumab) and MEDI4736 (Durvalumab)+Tremelimumab

Plus 6 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 6, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 3

Interventional

Where is it offered?196 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
AstraZeneca
Interventions being studied
Biological: MEDI4736 (Durvalumab); Biological: MEDI4736 (Durvalumab)+Tremelimumab; Drug: Paclitaxel + Carboplatin; Drug: Gemcitabine + Cisplatin; Drug: Gemcitabine + Carboplatin; Drug: Pemetrexed + Cisplatin; Drug: Pemetrexed + Carboplatin; Biological: Tremelimumab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Locally advanced→Metastatic or stage IV→
Biomarkers
EGFR→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • For inclusion in the study, patients should fulfill the following criteria:
  • Aged at least 18 years
  • Documented evidence of Stage IV NSCLC
  • No sensitizing EGFR mutation or ALK rearrangement
  • No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC
  • World Health Organization (WHO) Performance Status of 0 or 1
Reasons someone may not be able to joinExclusion criteria

Patients should not enter the study if any of the following

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteScottsdale, Arizona
  • Research SiteTucson, Arizona
  • Research SiteYuma, Arizona
  • Research SiteBakersfield, California
  • Research SiteFullerton, California
  • Research SiteLa Jolla, California
  • Research SiteLos Angeles, California
  • Research SiteLos Angeles, California
  • Research SiteRedondo Beach, California
  • Research SiteSacramento, California
  • Research SiteSan Luis Obispo, California
  • Research SiteSanta Maria, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 6, 2026. Always confirm current availability with the study team.

View original record ↗